Discovery & Development

Oligonucleotide-based therapeutics present manufacturers with specific processing and characterization challenges.

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.

Novo Nordisk's Stephen Gough explains how pharma can address the cardiovascular risks associated with type 2 diabetes.

How can we effectively manage the treatment of type 1 diabetes?

How can companies avoid the risks of HPAPI containment and handling?

Can machine learning offer mass spectrometry a boost for drug discovery?

Fujifilm Toyama's influenza treatment passes COVID-19 trial.

Exploring a new approach to treating IBS pain.

In what ways can the microbiome interact with oral medicines?

Why drug developers should take a fresh look at long-acting dosage forms.